Reviewing the Insider Trends for Novavax, Inc. (NVAX)

Rodiano Bonacci
Novembre 18, 2017

Cantor Fitzgerald reiterated their hold rating on shares of Novavax, Inc.

NVAX has been the topic of several research reports.

By taking a look at the stock's current statistics it can gauged that the stock candle is BULLISH with MEDIUM volatility.

Other research analysts have also issued reports about the company. This is based on a 1-5 numeric scale where Rating Scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell. Among holders that decreased their positions, 9 sold out of the stock Novavax, Inc. FBR & Co restated an "outperform" rating and set a $12.00 price objective on shares of Novavax in a report on Wednesday, January 18th. Three months ago, analysts assigned NVAX a 3.40 rating, which implies that analysts have become more optimistic about the outlook for the stock over the next year. The stock presently has a consensus rating of "Hold" and an average price target of $6.17.

Novavax (NASDAQ NVAX) traded up $0.07 on Wednesday, hitting $1.23.

The recent progress in the stock of Novavax, Inc. The return on assets stands at -52.6%, Return on Equity now is 452.8% and the Return on Investment value is 0%. Novavax has a 12 month low of $0.73 and a 12 month high of $1.78.

On Wednesday, Shares of Novavax, Inc. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. Novavax had a negative return on equity of 189.14% and a negative net margin of 1,908.41%. Novavax's revenue for the quarter was down 7.7% compared to the same quarter past year. The company has a 52-week low of $0.73 and a 52-week high of $1.78.

What Historical Figures Say About Novavax, Inc. "(NASDAQ:NVAX) Given "Hold" Rating at Cantor Fitzgerald" was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & global copyright legislation. The company has a 52-week low of $3.62 and a 52-week high of $14.32. Stock's twelve month price oscillated between $1.78 and $0.73. Novavax's revenue was up 158.5% compared to the same quarter last year. analysts expect that Novavax will post -0.63 earnings per share for the current fiscal year. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

In other Novavax news, insider Stanley C. Erck bought 100,000 shares of the company's stock in a transaction that occurred on Thursday, November 9th. The shares were acquired at an average cost of $1.13 per share, for a total transaction of $113,000.00. The disclosure for this sale can be found here. The stock volatility for the week was 4.66% while for the month was 5.29%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. HighTower Advisors LLC increased its holdings in Novavax by 3.8% in the first quarter. The stock had previously closed at $1.85, but opened at $1.63. Geduld E E purchased a new position in shares of Novavax during the third quarter valued at approximately $104,000. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company's stock worth $139,000 after purchasing an additional 455 shares during the period. Also, Director James F. Young sold 175,000 shares of the stock in a transaction on Thursday, August 31st. Profund Advisors LLC increased its holdings in Novavax by 0.4% in the second quarter. Finally, Amalgamated Bank raised its position in shares of Novavax by 1.1% in the second quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company's stock valued at $213,000 after buying an additional 10,965 shares during the last quarter.

Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The company operates in the Healthcare sector with a market capitalization of 363430.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE